Ocrelizumab (drug name Ocrevus), a new treatment for relapsing remitting MS has been recommended by NICE. Originally NICE had made a draft recommendation against the new drug, but changed their minds after feedback from a number of patients and other stakeholders.
It should be available on the NHS in England and Wales within the next 3 months for people who have Relapsing MS and are unwilling or unable to take Alemtuzumab.
